SCHEMBL194289

SCHEMBL194289

Cc1ccc2c(c[c]n2C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.44
MAPT P10636 1/20 0.44
CYP1A2 P05177 4/20 0.42
CYP2A6 P11509 3/20 0.42
TDP1 Q9NUW8 1/20 0.37
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
THRB P10828 1/20 0.35
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 1/20 0.34
NR1I2 O75469 1/20 0.34
AHR P35869 1/20 0.34
KMT2A Q03164 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 1/20 0.34
ACSS2 Q9NR19 1/20 0.34
PDE2A O00408 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1091680 0.83 CYP2A6 (0.42) RXFP1MAPTCYP1A2CYP2A6TDP1
SCHEMBL2056889 0.78 KDM4E (0.42) CYP1A2CYP2A6HTR2AHTR2CKDM4E
SCHEMBL1092086 0.78 HTR2A (0.37) RXFP1MAPTCYP2A6HTR2AHTR2C
SCHEMBL7835344 0.78 KDM4E (0.40) CYP1A2TDP1KDM4EMEN1KMT2A
SCHEMBL7822801 0.78 MCL1 (0.42) MAPTCYP2A6TDP1HTR2AHTR2C
SCHEMBL18940538 0.75 CYP2A6 (0.38) RXFP1MAPTCYP1A2CYP2A6TDP1
SCHEMBL137023 0.71 CA12 (0.39) MAPTCYP2A6HTR2AHTR2CKDM4E
SCHEMBL1091784 0.70 KCNQ3 (0.38) CYP1A2NPC1ALDH1A1RAB9ALMNA
SCHEMBL7835593 0.70 ALDH1A1 (0.49) MAPTCYP1A2TDP1THRBKDM4E
SCHEMBL3965207 0.65 HTR2C (0.37) CYP1A2CYP2A6HTR2AHTR2CKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8652752-B2 Sulphonium salt initiators BASF SE (DE) 2014-02-18 US claimed
EP-2197840-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-11-06 EP claimed
US-7893267-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2011-02-22 US claimed
US-20100297540-A1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2010-11-25 US claimed
EP-1863771-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS Transtech Pharma, Inc. (US) 2007-12-12 EP claimed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 US claimed
WO-2006099379-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS TRANSTECH PHARMA, INC. (US) 2006-09-21 WO claimed
CN-115504896-B Acrylic formate compound for LED photopolymerization, preparation method and application thereof 湖北固润科技股份有限公司 2024-05-07 CN disclosed
WO-2024078413-A1 ACRYLOYL FORMATE COMPOUND FOR LED PHOTOPOLYMERIZATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 湖北固润科技股份有限公司 2024-04-18 WO disclosed
CN-107463067-B Black photosensitive resin composition and application thereof 奇美实业股份有限公司 2024-01-26 CN disclosed
CN-117142995-A Pyruvic acid (hetero) arylthioester compound for LED photopolymerization and preparation and application thereof 湖北固润科技股份有限公司 2023-12-01 CN disclosed
CN-117142994-A Amphiphilic polyether alpha-ketone (hetero) arylthioester compound for LED photopolymerization and preparation and application thereof 湖北固润科技股份有限公司 2023-12-01 CN disclosed
US-20230142648-A1 OXIME ESTER PHOTOINITIATORS BASF SE (DE) 2023-05-11 US disclosed
EP-0842975-A1 Stabilising polyolefins for long term contact with an extracting medium Ciba SC Holding AG (CH) 1998-05-20 EP disclosed
WO-1998019693-A1 COMBINATORIAL LIBRARIES OF CYCLIC UREA AND CYCLIC THIOUREA DERIVATIVES AND COMPOUNDS THEREIN TREGA BIOSCIENCES, INC. (US) 1998-05-14 WO disclosed
EP-0839623-A1 Stabiliser combination for rotomolding process Ciba SC Holding AG (CH) 1998-05-06 EP disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
US-5516920-A POLYMER STABILIZERS CIBA-GEIGY CORPORATION (US) 1996-05-14 US disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297540-A1 SULPHONIUM SALT INITIATORS SULT1A1, SULT2A1, NCOA1 RXFP1 1610/4885MAPT 1627/4885CYP1A2 2387/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP RXFP1 4757/4885MAPT 85/4885CYP1A2 670/4885
US-20230142648-A1 OXIME ESTER PHOTOINITIATORS OCIAD1, OCIAD2, OXER1 RXFP1 2422/4885MAPT 579/4885CYP1A2 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.